Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - Marker Therapeutics, Inc. | tpiv10-k.htm |
| EX-31.1 - Marker Therapeutics, Inc. | exhib31-1.htm |
| EX-4.12 - Marker Therapeutics, Inc. | exhib4-12.htm |
| EX-31.2 - Marker Therapeutics, Inc. | exhib31-2.htm |
| EX-4.14 - Marker Therapeutics, Inc. | exhib4-14.htm |
| EX-4.15 - Marker Therapeutics, Inc. | exhib4-15.htm |
| EX-32.2 - Marker Therapeutics, Inc. | exhib32-2.htm |
| EX-4.13 - Marker Therapeutics, Inc. | exhib4-13.htm |
| EX-10.10 - Marker Therapeutics, Inc. | exhib10-10.htm |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The undersigned, Glynn Wilson, the Chief Executive Officer of TapImmune Inc. (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Annual Report on Form 10-K for the year ended December 31, 2010 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Annual Report on Form 10-K, as amended, fairly presents in all material respects the financial condition and results of operations of the Company.
| TapImmune Inc. | |||
|
Date: April 17, 2011
|
By:
|
/s/ Glynn Wilson | |
| Glynn Wilson | |||
| Chairman, Chief Executive Officer and Principal Executive Officer | |||